123 related articles for article (PubMed ID: 21081028)
21. Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial.
Price DK; Chau CH; Till C; Goodman PJ; Leach RJ; Johnson-Pais TL; Hsing AW; Hoque A; Parnes HL; Schenk JM; Tangen CM; Thompson IM; Reichardt JK; Figg WD
Cancer; 2016 Aug; 122(15):2332-40. PubMed ID: 27164191
[TBL] [Abstract][Full Text] [Related]
22. Risk Allele Frequency Analysis and Risk Prediction of Single-Nucleotide Polymorphisms for Prostate Cancer.
Yoon BW; Shin HT; Seo JH
Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360276
[TBL] [Abstract][Full Text] [Related]
23. Identification of genetic risk associated with prostate cancer using ancestry informative markers.
Ricks-Santi LJ; Apprey V; Mason T; Wilson B; Abbas M; Hernandez W; Hooker S; Doura M; Bonney G; Dunston G; Kittles R; Ahaghotu C
Prostate Cancer Prostatic Dis; 2012 Dec; 15(4):359-64. PubMed ID: 22801071
[TBL] [Abstract][Full Text] [Related]
24. CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification?
Kittles RA; Chen W; Panguluri RK; Ahaghotu C; Jackson A; Adebamowo CA; Griffin R; Williams T; Ukoli F; Adams-Campbell L; Kwagyan J; Isaacs W; Freeman V; Dunston GM
Hum Genet; 2002 Jun; 110(6):553-60. PubMed ID: 12107441
[TBL] [Abstract][Full Text] [Related]
25. CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer.
Zeigler-Johnson C; Friebel T; Walker AH; Wang Y; Spangler E; Panossian S; Patacsil M; Aplenc R; Wein AJ; Malkowicz SB; Rebbeck TR
Cancer Res; 2004 Nov; 64(22):8461-7. PubMed ID: 15548719
[TBL] [Abstract][Full Text] [Related]
26. Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and Other Caucasian populations.
Gervasini G; Vizcaino S; Gasiba C; Carrillo JA; Benitez J
Ther Drug Monit; 2005 Dec; 27(6):819-21. PubMed ID: 16306861
[TBL] [Abstract][Full Text] [Related]
27. Genetic variability of CYP3A4 in a heterogeneous Brazilian population from Maranhão.
Monteiro SC; de Sousa IH; Belfort IK; Nunes JD; Penha BA; dos Santos M; Drumond Louro I; da Silva ID
Genet Mol Res; 2016 Feb; 15(1):. PubMed ID: 26909985
[TBL] [Abstract][Full Text] [Related]
28. [CYP2D6, CYP3A5, and CYP3A4 gene polymorphism in Russian, Tatar, and Bashkir populations].
Mustafina OE; Tuktarova IA; Karimov DD; Somova Rs; Nasibullin TR
Genetika; 2015 Jan; 51(1):109-19. PubMed ID: 25857198
[TBL] [Abstract][Full Text] [Related]
29. CYP3A5 genetic polymorphisms in different ethnic populations.
Roy JN; Lajoie J; Zijenah LS; Barama A; Poirier C; Ward BJ; Roger M
Drug Metab Dispos; 2005 Jul; 33(7):884-7. PubMed ID: 15833928
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-8 genetic diversity, haplotype structure and production differ in two ethnically distinct South African populations.
Paximadis M; Picton ACP; Sengupta D; Ramsay M; Puren A; Tiemessen CT
Cytokine; 2021 Jul; 143():155489. PubMed ID: 33814271
[TBL] [Abstract][Full Text] [Related]
31. The 22Rv1 prostate cancer cell line carries mixed genetic ancestry: Implications for prostate cancer health disparities research using pre-clinical models.
Woods-Burnham L; Basu A; Cajigas-Du Ross CK; Love A; Yates C; De Leon M; Roy S; Casiano CA
Prostate; 2017 Dec; 77(16):1601-1608. PubMed ID: 29030865
[TBL] [Abstract][Full Text] [Related]
32. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism.
Wandel C; Witte JS; Hall JM; Stein CM; Wood AJ; Wilkinson GR
Clin Pharmacol Ther; 2000 Jul; 68(1):82-91. PubMed ID: 10945319
[TBL] [Abstract][Full Text] [Related]
33. Sequence diversity and haplotype structure at the human CYP3A cluster.
Thompson EE; Kuttab-Boulos H; Yang L; Roe BA; Di Rienzo A
Pharmacogenomics J; 2006; 6(2):105-14. PubMed ID: 16314882
[TBL] [Abstract][Full Text] [Related]
34. CYP3A5 3, CYP3A4 1B and MDR1 C3435T genotype distributions in Ecuadorians.
Sinués B; Vicente J; Fanlo A; Mayayo-Sinués E; González-Andrade F; Sánchez-Q D; Martínez-Jarreta B
Dis Markers; 2008; 24(6):325-31. PubMed ID: 18688081
[TBL] [Abstract][Full Text] [Related]
35. Genetic diversity of CYP3A4 and CYP3A5 polymorphisms in North African populations from Morocco and Tunisia.
Novillo A; Romero-Lorca A; Gaibar M; Bahri R; Harich N; Sánchez-Cuenca D; Esteban E; Fernández-Santander A
Int J Biol Markers; 2015 Feb; 30(1):e148-51. PubMed ID: 25385241
[TBL] [Abstract][Full Text] [Related]
36. Spectrum of mitochondrial genomic variation and associated clinical presentation of prostate cancer in South African men.
McCrow JP; Petersen DC; Louw M; Chan EK; Harmeyer K; Vecchiarelli S; Lyons RJ; Bornman MS; Hayes VM
Prostate; 2016 Mar; 76(4):349-58. PubMed ID: 26660354
[TBL] [Abstract][Full Text] [Related]
37. The PXR rs7643645 polymorphism is associated with the risk of higher prostate-specific antigen levels in prostate cancer patients.
Reyes-Hernández OD; Vega L; Jiménez-Ríos MA; Martínez-Cervera PF; Lugo-García JA; Hernández-Cadena L; Ostrosky-Wegman P; Orozco L; Elizondo G
PLoS One; 2014; 9(6):e99974. PubMed ID: 24924803
[TBL] [Abstract][Full Text] [Related]
38. The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer.
Vaarala MH; Mattila H; Ohtonen P; Tammela TL; Paavonen TK; Schleutker J
Int J Cancer; 2008 Jun; 122(11):2511-6. PubMed ID: 18306354
[TBL] [Abstract][Full Text] [Related]
39. CYP3A5*3 polymorphism and cancer risk: a meta-analysis and meta-regression.
Wang BS; Liu Z; Xu WX; Sun SL
Tumour Biol; 2013 Aug; 34(4):2357-66. PubMed ID: 23584898
[TBL] [Abstract][Full Text] [Related]
40. Functional polymorphisms in the CYP3A4, CYP3A5, and CYP21A2 genes in the risk for hypertension in pregnancy.
Coto E; Tavira B; Marín R; Ortega F; López-Larrea C; Ruiz-Ortega M; Ortiz A; Díaz M; Corao AI; Alonso B; Alvarez V
Biochem Biophys Res Commun; 2010 Jul; 397(3):576-9. PubMed ID: 20617557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
